Fintel reports that on May 26, 2023, EF Hutton reiterated coverage of Allogene Therapeutics (NASDAQ:ALLO) with a Buy recommendation.
Analyst Price Forecast Suggests 228.07% Upside
As of May 11, 2023, the average one-year price target for Allogene Therapeutics is 17.95. The forecasts range from a low of 6.06 to a high of $36.75. The average price target represents an increase of 228.07% from its latest reported closing price of 5.47.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Allogene Therapeutics is 4MM, an increase of 1,602.99%. The projected annual non-GAAP EPS is -2.83.
What is the Fund Sentiment?
There are 397 funds or institutions reporting positions in Allogene Therapeutics. This is an increase of 1 owner(s) or 0.25% in the last quarter. Average portfolio weight of all funds dedicated to ALLO is 0.11%, a decrease of 18.92%. Total shares owned by institutions increased in the last three months by 3.86% to 130,342K shares. The put/call ratio of ALLO is 0.60, indicating a bullish outlook.
What are Other Shareholders Doing?
Tpg Gp A holds 18,716K shares representing 12.83% ownership of the company. No change in the last quarter.
XBI – SPDR(R) S&P(R) Biotech ETF holds 7,306K shares representing 5.01% ownership of the company. In it’s prior filing, the firm reported owning 5,040K shares, representing an increase of 31.02%. The firm decreased its portfolio allocation in ALLO by 28.14% over the last quarter.
Price T Rowe Associates holds 6,330K shares representing 4.34% ownership of the company. In it’s prior filing, the firm reported owning 5,942K shares, representing an increase of 6.14%. The firm decreased its portfolio allocation in ALLO by 22.13% over the last quarter.
Primecap Management holds 5,769K shares representing 3.96% ownership of the company. In it’s prior filing, the firm reported owning 4,944K shares, representing an increase of 14.30%. The firm decreased its portfolio allocation in ALLO by 12.71% over the last quarter.
Capital International Investors holds 5,310K shares representing 3.64% ownership of the company. No change in the last quarter.
Allogene Therapeutics Background Information
(This description is provided by the company.)
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of ‘off-the-shelf’ CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.
Key filings for this company:
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
